![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 13
2022
Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno, Naoto T.; Prat, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil-Gil, Miguel; Li, Wei; Pierga, Jean-Yves; Im, Seock-Ah; Moore, Halle C. F.; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung-Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia und Cameron, David A.
(2022):
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
In: New England Journal of Medicine, Bd. 387, Nr. 1: S. 9-20
Lu, Yen-Shen; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young-Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan und Tripathy, Debu
(2022):
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 5: S. 851-859
Cristofanilli, Massimo; Rugo, Hope S.; Im, Seock-Ah; Slamon, Dennis J.; Harbeck, Nadia; Bondarenko, Igor; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Iwata, Hiroji; O'Leary, Ben; Andre, Fabrice; Loibl, Sibylle; Bananis, Eustratios; Liu, Yuan; Huang, Xin; Kim, Sindy; Frean, Maria Jose Lechuga und Turner, Nicholas C.
(2022):
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
In: Clinical Cancer Research, Bd. 28, Nr. 16: S. 3433-3442
Krop, Ian E.; Im, Seock-Ah; Barrios, Carlos; Bonnefoi, Herve; Gralow, Julie; Toi, Masakazu; Ellis, Paul A.; Gianni, Luca; Swain, Sandra M.; Im, Young-Hyuck; De Laurentiis, Michelino; Nowecki, Zbigniew; Huang, Chiun-Sheng; Fehrenbacher, Louis; Ito, Yoshinori; Shah, Jigna; Boulet, Thomas; Liu, Haiying; Macharia, Harrison; Trask, Peter; Song, Chunyan; Winer, Eric P. und Harbeck, Nadia
(2022):
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
In: Journal of Clinical Oncology, Bd. 40, Nr. 5: S. 438-448
2021
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock-Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Villanueva Vazquez, Rafael; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu und Lu, Yen-Shen
(2021):
Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
In: Jco Precision Oncology, Bd. 5: S. 1408-1420
Winer, Eric P.; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime und Cortes, Javier
(2021):
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
In: Lancet Oncology, Bd. 22, Nr. 4: S. 499-511
2020
Finn, Richard S.; Liu, Yuan; Zhu, Zhou; Martin, Miguel; Rugo, Hope S.; Dieras, Veronique; Im, Seock-Ah; Gelmon, Karen A.; Harbeck, Nadia; Lu, Dongrui R.; Gauthier, Eric; Bartlett, Cynthia Huang und Slamon, Dennis J.
(2020):
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer.
In: Clinical Cancer Research, Bd. 26, Nr. 1: S. 110-121
2018
Tripathy, Debu; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Harbeck, Nadia; Hurvitz, Sara A.; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; Laurentiis, Michelino de; Im, Young-Hyuck; Kümmel, Sherko; El-Saghir, Nagi; Liu, Mei-Ching; Carlson, Gary; Hughes, Gareth; Diaz-Padilla, Ivan; Germa, Caroline; Hirawat, Samit und Lu, Yen-Shen
(2018):
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 7: S. 904-915
Rugo, Hope S.; Turner, Nicholas C.; Finn, Richard S.; Joy, Anil A.; Verma, Sunil; Harbeck, Nadia; Masuda, Norikazu; Im, Seock-Ah; Huang, Xin; Kim, Sindy; Sun, Wan; Iyer, Shrividya; Schnell, Patrick; Bartlett, Cynthia Huang und Johnston, Stephen
(2018):
Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
In: European Journal of Cancer, Bd. 101: S. 123-133
2017
Loibl, Sibylle; Turner, Nicholas C.; Ro, Jungsil; Cristofanilli, Massimo; Iwata, Hiroji; Im, Seock-Ah; Masuda, Norikazu; Loi, Sherene; Andre, Fabrice; Harbeck, Nadia; Verma, Sunil; Folkerd, Elizabeth; Theall, Kathy Puyana; Hoffman, Justin; Zhang, Ke; Bartlett, Cynthia Huang und Dowsett, Mitchell
(2017):
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
In: Oncologist, Bd. 22, Nr. 9: S. 1028-1038
2016
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe und Piccart-Gebhart, Martine
(2016):
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
In: Lancet Oncology, Bd. 17, Nr. 3: S. 357-366
Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria und Slamon, Dennis
(2016):
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
In: Lancet Oncology, Bd. 17, Nr. 4: S. 425-439
Finn, Richard S.; Martin, Miguel; Rugo, Hope S.; Jones, Stephen; Im, Seock-Ah; Gelmon, Karen; Harbeck, Nadia; Lipatov, Oleg N.; Walshe, Janice M.; Moulder, Stacy; Gauthier, Eric; Lu, Dongrui R.; Randolph, Sophia; Diéras, Véronique und Slamon, Dennis J.
(2016):
Palbociclib and Letrozole in Advanced Breast Cancer.
In: New England Journal of Medicine, Bd. 375, Nr. 20: S. 1925-1936